Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey

Paolo Cantù, Ilaria Parzanese, Valerio Balassone, Antonio Sario, Fiammetta Soggiu, Giovanni Lombardi, Federico Barbaro, Antonio Pisani, Anna Baldan, Giulio Cariani, Valentina Boarino, Alberto Fasoli, Helga Bertani, Edoardo Forti, Milutin Bulajic, Davide Ghinolfi, Elena Nadal, Angelo Cerofolini, Luca Barresi, Giorgia Catalano, Italo Stroppa, Sara Traini, Vincenzo Mazzaferro, Livio Cipolletta, Andrea Tringali, Guido Costamagna, Paolo Ravelli, Franco Bazzoli, Alberto Merighi, Maria Caterina Parodi, Rita Conigliaro, Massimiliano Mutignani, Maurizio Zilli, Franco Filipponi, Alberto Fantin, Luca

Transplant‐related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma

George N. Ioannou – 22 December 2016 – Transplant‐related survival benefit is calculated as the difference between life expectancy with transplantation and life expectancy without transplantation.

Neutrophil‐to‐lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end‐stage liver disease patients with cirrhosis

Avash Kalra, Joel P. Wedd, Kiran M. Bambha, Jane Gralla, Lucy Golden‐Mason, Christine Collins, Hugo R. Rosen, Scott W. Biggins – 22 December 2016 – The Model for End‐Stage Liver Disease (MELD) score has reduced accuracy for liver transplantation (LT) wait‐list mortality when MELD ≤ 20. Neutrophil‐to‐lymphocyte ratio (NLR) is a biomarker associated with systemic inflammation and may predict cirrhotic decompensation and death. We aimed to evaluate the prognostic utility of high NLR (≥4) for liver‐related death among low MELD patients listed for LT, controlling for stage of cirrhosis.

Impact of emergency adult living donor liver transplantation on the survival of patients with antituberculosis therapy‐induced acute liver failure

Jin‐Young Huh, Danbi Lee, Jihyun Ahn, Ju Hyun Shim, Young‐Suk Lim, Gil‐Chun Park, Gi‐Won Song, Ki‐Hun Kim, Dong‐Hwan Jung, Deok‐Bog Moon, Shin Hwang, Sung Gyu Lee, Sei Won Lee, Jin‐Woo Song, Yeon‐Mok Oh, Tae Sun Shim, Kyung‐Wook Jo – 22 December 2016

Update on pharmacotherapies for cholestatic liver disease

Ahmad H. Ali, James H. Tabibian, Keith D. Lindor – 21 December 2016 – Cholestatic liver diseases are conditions with impaired bile formation and/or flow due to genetic, immunologic, environmental, or other causes. Unless successfully treated, this can lead to chronic liver injury and end‐stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) embody the most prominent adult cholestatic liver diseases with regard to incidence, morbidity, and mortality.

The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection

William F. Balistreri, Karen F. Murray, Philip Rosenthal, Sanjay Bansal, Chuan‐Hao Lin, Kathryn Kersey, Benedetta Massetto, Yanni Zhu, Bittoo Kanwar, Polina German, Evguenia Svarovskaia, Diana M. Brainard, Jessica Wen, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, Kathleen Schwarz – 20 December 2016 – No all‐oral, direct‐acting antiviral regimens have been approved for children with chronic hepatitis C virus (HCV) infection.

Subscribe to